About: CoViD-19 Immunopathology and Immunotherapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CoViD-19 Immunopathology and Immunotherapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	CoViD-19 Immunopathology and Immunotherapy
Creator	Chiappelli, Francesco Endo, Greenberg, Gillian Khakshooy, Allen
Source	Medline; PMC; WHO
abstract	New evidence on the T-cell immuno-pathology in patient’s with Corona Virus Disease 2019 (CoViD-19) was reported by Diao et al. in MedRxiv (doi: 10.1101/2020.02.18.20024364) [1]. It reports observations on 522 patients with confirmed CoViD-19 symptomatology, compared to 40 control subjects. In brief, notable T cytopoenia was recorded by flow cytometry in the CD4+ and the CD8+ populations, which were significantly yet inversely correlated with remarkably increased serum levels of the pro-inflammatory cytokines IL-6, IL-10 and TNF-a. Flow cytometry established a progressive increase in the expression of programmed cell death marker-1 (PD-1) and T cell immunoglobulin and mucin domain 3 (Tim-3) as patients (n=14) deteriorated from prodromal to symptomatic CoViD-19 requiring intensive care. Here, we interpret these observations of Diao et al from our current understanding of T cell immunophysiology and immunopathology following an immune challenge in the form of sustained viral infection, as is the case in CoViD-19, with emphasis on exhausted T cells (Tex). Recent clinical trials to rescue Tex show promising outcomes. The relevance of these interventions for the prevention and treatment of CoViD-19 is discussed. Taken together, the data of Diao et al could proffer the first glimpse of immunopathology and possible immunotherapy for patients with CoViD-19.
has issue date	2020-03-31(xsd:dateTime)
bibo:doi	10.6026/97320630016219
bibo:pmid	32308263
has license	cc-by
sha1sum (hex)	8599d8593f16d032b0a4f6b8f447e410b5bc7b6e
schema:url	https://doi.org/10.6026/97320630016219
resource representing a document's title	CoViD-19 Immunopathology and Immunotherapy
has PubMed Central identifier	PMC7147500
has PubMed identifier	32308263
schema:publication	Bioinformation
resource representing a document's body	covid:8599d8593f16d032b0a4f6b8f447e410b5bc7b6e#body_text
is schema:about of	named entity 'CoViD-19' named entity 'immunoglobulin' named entity 'programmed cell death' named entity 'T cell' named entity 'mucin' named entity 'compared' named entity 'CASE' named entity 'PREVENTION' named entity 'SYMPTOMATOLOGY' named entity 'COVID-19' named entity 'PROGRESSIVE' named entity 'ESTABLISHED' named entity 'PRO-' named entity '28PD' named entity 'IMMUNE' named entity 'OUTCOMES' named entity 'INTERPRET' named entity 'INTENSIVE CARE' named entity 'THESE' named entity 'INCREASED' named entity 'IMMUNOPATHOLOGY' named entity 'IMMUNOPHYSIOLOGY' named entity 'INCREASE' named entity 'CD8' named entity 'TREATMENT' named entity 'PRODROMAL' named entity 'SYMPTOMATIC' named entity 'REPORTS' named entity 'POPULATIONS' named entity 'PROGRAMMED CELL DEATH' named entity 'CoViD-19' named entity 'IL-6' named entity 'CoViD-19' named entity 'Tex' named entity 'immunopathology' named entity 'populations' named entity 'T cell' named entity 'inversely' named entity 'Volume' named entity 'CoViD-19' named entity 'CoViD-19' named entity 'IL-6' named entity 'control subjects' named entity 'Immunotherapy' named entity 'CoViD-19' named entity 'epigenetic' named entity 'physiological balance' named entity 'PD-1' named entity 'non-peptide' named entity 'mitochondrial' named entity 'IL-2' named entity 'checkpoint blockade' named entity 'programmed cell death' named entity 'antibodies' named entity 'statistical modeling' named entity 'PD-1' named entity 'apoptosis' named entity 'cytotoxic' named entity 'CD8+ T cell' named entity 'IL-6' named entity 'C8+' named entity 'CD8+ T cells' named entity 'allostasis' named entity 'viral infections' named entity 'pro-inflammatory cytokines' named entity 'lymphocytes' named entity 'cytokines' named entity 'CD4' named entity 'PD-1' named entity 'co-receptor' named entity 'antigen-presenting cells' named entity 'Dengue virus' named entity 'programmed cell death' named entity 'testosterone' named entity 'viral infections' named entity 'CoViD-19' named entity 'CD28' named entity 'anergic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software